GTx, Inc. (GTXI) Given $16.50 Consensus Target Price by Analysts

Shares of GTx, Inc. (NASDAQ:GTXI) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 12-month consensus price target of $16.50 for the company and are expecting that the company will post ($0.39) earnings per share for the current quarter, according to Zacks. Zacks has also given GTX an industry rank of 158 out of 265 based on the ratings given to related companies.

Several research analysts recently commented on the company. Robert W. Baird assumed coverage on GTX in a research report on Tuesday, November 21st. They set an “outperform” rating and a $17.00 price target for the company. Zacks Investment Research cut GTX from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, Stifel Nicolaus assumed coverage on GTX in a research report on Thursday, November 9th. They set a “buy” rating for the company.

Shares of GTX (GTXI) traded up $0.41 during midday trading on Monday, reaching $11.56. The company had a trading volume of 29,734 shares, compared to its average volume of 55,492. GTX has a 1 year low of $2.73 and a 1 year high of $13.35. The firm has a market capitalization of $240.19, a PE ratio of -6.61 and a beta of 1.77.

GTX (NASDAQ:GTXI) last issued its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.25). equities analysts forecast that GTX will post -1.61 earnings per share for the current year.

In related news, VP Henry Patton Doggrell sold 4,965 shares of the stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $11.33, for a total transaction of $56,253.45. Following the completion of the transaction, the vice president now directly owns 54,804 shares of the company’s stock, valued at $620,929.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jason T. Shackelford sold 3,090 shares of the stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $11.33, for a total value of $35,009.70. Following the transaction, the insider now directly owns 31,111 shares of the company’s stock, valued at $352,487.63. The disclosure for this sale can be found here. Insiders have sold 15,364 shares of company stock valued at $174,074 over the last three months. Insiders own 41.20% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in GTXI. Abingworth LLP acquired a new stake in shares of GTX in the third quarter valued at approximately $2,781,000. Caxton Corp acquired a new stake in shares of GTX in the third quarter valued at approximately $531,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of GTX in the second quarter valued at approximately $124,000. 11.57% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/11/gtx-inc-gtxi-given-16-50-consensus-target-price-by-analysts.html.

GTX Company Profile

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

Get a free copy of the Zacks research report on GTX (GTXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply